Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 3
Dual Glucagon and GLP-1 Agonists: Review
A 2026 narrative review maps dual glucagon and GLP-1 agonists for obesity and MASH, while head-to-head evidence remains unresolved.
Ozempic Face and Facial Aging: 2026 Review
A 2026 dermatology review frames so-called Ozempic face as weight-loss-associated facial change, not a proven drug-specific diagnosis.
Incretin Therapy Before Pregnancy in PCOS
A target trial emulation linked preconception incretin therapy with fewer adverse pregnancy outcomes than metformin, but it cannot prove causation.
SELECT-Eligible MI Risk in Western Denmark
A Danish registry study found substantial five-year cardiovascular risk after a first heart attack among SELECT-eligible patients without diabetes.
SURMOUNT-OSA: Symptoms and Readouts
A SURMOUNT-OSA post hoc analysis found larger reported symptom gains from tirzepatide among people with worse symptoms at baseline.
Tirzepatide vs sleeve gastrectomy
A matched 2026 cohort compared 12-month weight loss after tirzepatide treatment or sleeve gastrectomy in severe obesity.
AI as a commercial health determinant
A BMJ commentary frames AI as a commercial determinant of health. Persuasion and misinformation studies show why the concern deserves testing.
Bariatric procedures vs semaglutide costs
A UK model compared sleeve gastroplasty, sleeve gastrectomy and a gastric balloon with semaglutide over five years.
FLOW and SGLT2 inhibitors in CKD
FLOW established kidney-outcome evidence for semaglutide in diabetic CKD. A translational review explains why SGLT2 combination trials are next.
Generic semaglutide and diabetes value
A Canadian analysis estimated how far GLP-1 receptor agonist prices would need to fall to become cost-effective.
GLP-1 Drugs and Alcohol Hospitalisation
A target-trial emulation linked semaglutide and tirzepatide initiation with fewer alcohol-related hospitalisations, with confounding concerns.
GLP-1 Safety Signals in FAERS
A 2026 GLP-1 pharmacovigilance study used sensitivity tests and a second database to separate stable safety signals from fragile ones.